Compare FMY & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMY | VERU |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 45.0M |
| IPO Year | 2005 | 1996 |
| Metric | FMY | VERU |
|---|---|---|
| Price | $11.43 | $2.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 2.6K | ★ 241.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.40 | $2.05 |
| 52 Week High | $12.38 | $7.33 |
| Indicator | FMY | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 56.44 |
| Support Level | N/A | $2.12 |
| Resistance Level | $11.80 | $2.87 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 1.91 | 66.18 |
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.